Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Accreditation Certification ISQua EEA

 
The Ministry of Public Health (MOPH) is proud to announce the reception of the prestigious Award by the International Society for Quality in Health Care – External Evaluation Association (ISQua EEA) for the Accreditation Standards of Hospitals in Lebanon 2022 Edition.

This development marks a crucial step forward for quality improvement and the enhancement of patient safety culture with internationally recognized standards.

Given the principal importance of improving healthcare management, quality of care, and patient safety in our hospitals, especially in these challenging times in Lebanon, we are committed to maintaining the accreditation process as an integral part of continuous healthcare improvement in Lebanon, with teams/trainers dedicated to improving care in hospitals, 44 trained surveyors and more than 500 health professionals from all hospitals in Lebanon currently being trained.

Special recognition goes to Dr. Walid Ammar for his leadership and guidance in transforming the hospital accreditation system in Lebanon.

We would like to extend our gratitude to Dr. Fadi El-Jardali and his team for their exceptional work in revising and improving the accreditation standards and tools. We also thank Dr. Ali Elhaj for his contributions during the initial phase of standards revision.

We are deeply grateful the financial support of AFD, to the Haute Autorité de Santé (HAS France) and all individuals who offered their advice and technical support, especially Dr. Bruno Lucet for his complete support during all the preparation process for the ISQua EEA certification.

We express our sincere appreciation to the Comité Technique d’Accréditation Hospitalière (CTAH) for their valuable feedback and suggestions, as well as the National Hospital Accreditation Committee (CNAH) including the main stakeholders: Ecole Supérieure des Affaires (ESA), Syndicate of Hospitals, Order of Physicians, Order of Nurses, Order of Pharmacists, Order of Midwives, Lebanese National Committee of Blood Transfusion, Army Medical Services, NSSF, MFE, and various faculties of medicine. We would like to acknowledge their contributions and their unwavering support.

Additionally, we extend our warm thanks to the national experts for their invaluable feedback and suggestions on the standards.

A special thanks to Perrine Malaud Wakim and the team of Pôle Santé at for their continuous dedication and support.

#Healthcare #Quality #Accreditation #Standards # Patient Safety Culture #MOPH #ESA #AFD #HAS #CNAH #CTAH #
    ...
    112
    ...
ATC Name B/G Ingredients Dosage Form Price
L01EG02 AFINITOR B Everolimus - 10mg 10mg Tablet 205,782,764 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 10mg 10mg Tablet 88,257,720 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 10mg 10mg Tablet 124,701,632 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 2.5mg 2.5mg Tablet 55,600,246 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 2.5mg 2.5mg Tablet 52,290,378 L.L
L01EH01 TYKERB B Lapatinib ditosylate - 250mg 250mg Tablet, film coated 98,434,399 L.L
L01EJ01 CELEZON G Ruxolitinib - 5mg 5mg Tablet L.L
L01EJ01 CELEZON G Ruxolitinib - 15mg 15mg Tablet L.L
L01EJ01 CELEZON G Ruxolitinib - 20mg 20mg Tablet L.L
L01EJ01 JAKAVI B Ruxolitinib - 5mg 5mg Tablet 165,514,059 L.L
L01EJ01 CELEZON G Ruxolitinib - 5mg 5mg Tablet 95,532,998 L.L
L01EJ01 JAKAVI B Ruxolitinib - 15mg 15mg Tablet 326,608,760 L.L
L01EJ01 CELEZON G Ruxolitinib - 15mg 15mg Tablet 188,515,591 L.L
L01EJ01 JAKAVI B Ruxolitinib - 20mg 20mg Tablet 326,608,760 L.L
L01EJ01 CELEZON G Ruxolitinib - 20mg 20mg Tablet 188,515,591 L.L
L01EK01 INLYTA B Axitinib - 5mg 5mg Tablet, film coated 184,486,511 L.L
L01EK01 INLYTA B Axitinib - 1mg 1mg Tablet, film coated 57,595,789 L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated L.L
L01EL01 DULLARMA G Ibrutinib - 140mg 140mg Capsule, hard L.L
L01EL01 IMBRUVICA B Ibrutinib - 140mg 140mg Tablet, film coated 187,342,573 L.L
L01EL01 DULLARMA G Ibrutinib - 140mg 140mg Capsule, hard 422,860,803 L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated 562,026,556 L.L
L01EL02 CALQUENCE B Acalabrutinib - 100mg 100mg Capsule 650,653,454 L.L
L01EM03 PIQRAY B Alpelisib - 150mg 150mg Tablet, film coated 359,195,954 L.L
L01EM03 PIQRAY B Alpelisib - 200mg, Alpelisib - 50mg 150mg Tablet, film coated 359,195,954 L.L
L01EM03 PIQRAY B Alpelisib - 200mg 200mg Tablet, film coated 359,195,954 L.L
L01EX01 SUTENT B Sunitinib maleate - 12.5mg 12.5mg Capsule L.L
L01EX01 SUTENT B Sunitinib maleate - 50mg 50mg Capsule L.L
L01EX01 SUTENT B Sunitinib maleate - 12.5mg 12.5mg Capsule 54,006,801 L.L
L01EX01 SOVIDEX G Sunitinib maleate - 12.5mg 12.5mg Capsule 36,042,560 L.L
    ...
    112
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025